News

Latest news

Hide mandatory notifications of trade

Bionor Pharma ASA – Extraordinary General Meeting

(Oslo, Norway, 12 February 2016) Bionor Pharma ASA (OSE:BIONOR), a biopharmaceutical company focused on advancing a functional cure for HIV, has received a request from Lars Høie and certain other shareholders, who jointly hold approximately 30 per cent of the share capital in the company, that an extraordinary general meeting be held for the election of a new board of directors of the company.

Pursuant to Section 5-7 (2) of the Norwegian Public Limited Liability Companies Act, shareholders holding more than 5% of the share capital may require that an extraordinary meeting is called for to address specified matters. Such extraordinary general meeting shall be held within one month. The Board of Directors will therefore call for an extraordinary general meeting to be held no later than 11 March 2016.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Further information
David Horn Solomon, President and CEO, +45 22 20 63 00, dhs@bionorpharma.com
Jens Krøis, CFO, +45 20 80 16 68, jk@bionorpharma.com
Jørgen Fischer Ravn, VP Investor Relations & Communications, +45 20 30 39 03, jfr@bionorpharma.com

About Bionor
Bionor Pharma is a Norwegian biopharmaceutical company focused on advancing its proprietary therapeutic vaccine Vacc-4x in combination with other medicines toward a functional HIV cure. The company believes it has first mover potential based on clinical results to date and early adoption of now recognized clinical strategy. In December 2015, Bionor announced that the HIV ’Shock & Kill’ trial REDUC with Vacc-4x and romidepsin successfully met its primary endpoint by significantly reducing latent HIV reservoir and further demonstrated control of viral load. Bionor is currently planning BIOSKILL, a proof-of-concept Phase II trial, which may lead to a major value inflection point and partnering opportunities. Bionor currently retains full ownership rights to Vacc-4x, i.e., the upside potential from partnering or licensing remains with the company. Bionor is based in Oslo, Norway, and also has offices in Copenhagen, Denmark and New York, USA. Bionor is listed on Oslo Børs (OSE:BIONOR). More information about Bionor is available at www.bionorpharma.com.

Announcement as PDF.